BiotechTube
Home/Byondis/Marco Timmers, Ph.D.
MT

Marco Timmers, Ph.D.

Chief Executive Officer

Byondis

Therapeutic Areas

Oncology

Byondis Pipeline

DrugIndicationPhase
[vic-]trastuzumab duocarmazine (SYD985)HER2-positive metastatic breast cancerPhase 3
SYD1875Solid Tumors (Target X)Preclinical

Leadership Team at Byondis

PW
Piet Wigerinck, Ph.D.
Chief Scientific Officer
View full Byondis profile